I've got a part-time job how to make ashwagandha powder at home in hindi The deal has more to do with financial planning than drug making, but that should hardly bother Elan’s shareholders. Investors will receive $6.25 a share in cash, about half as much again as is sitting on Elan’s balance sheet. True, some biotech aficionados may have little interest in shares in a consumer-drugs company. But, while Perrigo shares fell Monday, the stock would have to be overvalued by about 28% for the deal to fall shy of Royalty’s offer, notes Deutsche Bank.
|